Literature DB >> 12100793

Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial.

Eberhard Biermann1, Wolfgang Dietrich, Julian Rihl, Eberhard Standl.   

Abstract

BACKGROUND: Patients with insulin dependent diabetes require frequent advice if their metabolic control is not optimal. This study focuses on the fiscal and administrative aspects of telemanagement, which was used to establish a supervised autonomy of patients on intensified insulin therapy.
METHODS: A prospective, randomised trial with 43 patients on intensified insulin therapy was conducted. Travelling distance to the diabetes centre was 50 min one way; all patients had undergone a diabetes education course with lessons in dose adaptation. Patients were randomly assigned to telecare (n=27) or conventional care (n=16). They used BG-meters with a storage capacity of 120 values (Precision QID Abbott/Medisense) and transmitted their data over a combined modem/interface via telephone line to the diabetes centre. Data were displayed and stored by a customised software (Precision Link Plus, Abbott/Medisense). Advice for proper dose adjustment was given by telephone.
RESULTS: Average time needed for instruction in the telemedical system was 15 min. Data were transmitted every 1-3 weeks and a teleconsultation was performed by phone every 2-4 weeks, depending on the extent of specific problems. On average, personal visits in the control group were performed once a month. Physician's time expenditure for telemanagement, compared to conventional advice was moderately higher (50 vs. 42 min per month). A substantial amount of time on the patients side could be saved through replacing personal communications by telephone contacts and data transmission reduction (96 vs. 163 min/month including data transmission time). Setting up an optimal telemanagement scenario, a cost analysis was carried out yielding savings of approximately 650 euro per year per patient. HbA(1c) dropped significantly from 8.2 to 7.0% after 8 months of observation, but there was no significant difference between the intervention and control groups. Major technical problems with the telematic system did not occur during the study.
CONCLUSIONS: Telemanagement of insulin-requiring diabetic patients is a cost and time saving procedure for the patients and results in metabolic control comparable to conventional outpatient management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100793     DOI: 10.1016/s0169-2607(02)00037-8

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  30 in total

1.  Service design attributes affecting diabetic patient preferences of telemedicine in South Korea.

Authors:  Hayoung Park; Yucheong Chon; Jongsu Lee; Ie-Jung Choi; Kun-Ho Yoon
Journal:  Telemed J E Health       Date:  2011-06-01       Impact factor: 3.536

2.  Development, validation, and use of English and Spanish versions of the telemedicine satisfaction and usefulness questionnaire.

Authors:  Suzanne Bakken; Lorena Grullon-Figueroa; Roberto Izquierdo; Nam-Ju Lee; Philip Morin; Walter Palmas; Jeanne Teresi; Ruth S Weinstock; Steven Shea; Justin Starren
Journal:  J Am Med Inform Assoc       Date:  2006-08-23       Impact factor: 4.497

3.  The effects of a web-based intervention on the physical outcomes associated with diabetes among adults age 60 and older: a randomized trial.

Authors:  Gail E Bond; Robert Burr; Fredric M Wolf; Martha Price; Susan M McCurry; Linda Teri
Journal:  Diabetes Technol Ther       Date:  2007-02       Impact factor: 6.118

Review 4.  A systematic review of the key indicators for assessing telehomecare cost-effectiveness.

Authors:  Stephanie Vergara Rojas; Marie-Pierre Gagnon
Journal:  Telemed J E Health       Date:  2008-11       Impact factor: 3.536

Review 5.  Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials.

Authors:  Labib Imran Faruque; Natasha Wiebe; Arash Ehteshami-Afshar; Yuanchen Liu; Neda Dianati-Maleki; Brenda R Hemmelgarn; Braden J Manns; Marcello Tonelli
Journal:  CMAJ       Date:  2016-10-31       Impact factor: 8.262

6.  Optimizing mHealth Technologies in Real-World Clinical Practices.

Authors:  Pablo Mora; William C Biggs; Christopher G Parkin
Journal:  Clin Diabetes       Date:  2019-07

7.  Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity.

Authors:  N Kearney; L McCann; J Norrie; L Taylor; P Gray; M McGee-Lennon; M Sage; M Miller; R Maguire
Journal:  Support Care Cancer       Date:  2008-10-25       Impact factor: 3.603

8.  Home telemonitoring for type 2 diabetes: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-10-01

9.  Can economic evaluation in telemedicine be trusted? A systematic review of the literature.

Authors:  Trine S Bergmo
Journal:  Cost Eff Resour Alloc       Date:  2009-10-24

10.  Active care management supported by home telemonitoring in veterans with type 2 diabetes: the DiaTel randomized controlled trial.

Authors:  Roslyn A Stone; R Harsha Rao; Mary Ann Sevick; Chunrong Cheng; Linda J Hough; David S Macpherson; Carol M Franko; Rebecca A Anglin; D Scott Obrosky; Frederick R Derubertis
Journal:  Diabetes Care       Date:  2009-12-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.